All In MedTech

Device Trial Radar · NCT01317160

Compression Treatment Effects on Complications and Healing of Achilles Tendon Rupture

Intermittent Pneumatic Compression Effects on Venous Thromboembolism Incidence and Healing of Achilles Tendon Rupture

Last checked: Nov 19, 2026Latest source record: Mar 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Mar 2011

Primary completion

Aug 2015

Study completion Sep 2018

Sponsor

Lead sponsor
Karolinska University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Region Stockholm; DJO Incorporated
First posted
Mar 17, 2011

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (care provider, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective randomized study aims to determine whether intermittent pneumatic compression (IPC), 75 patients, beneath functional bracing compared to treatment-as-usual in plaster cast, 75 patients, can reduce the Venous Thromboembolism (VTE) incidence and promote healing of sutured acute Achilles tendon ruptures. At two weeks post surgery, the IPC intervention will be ended and both patient groups will be immobilized in an orthosis until follow-up at six weeks. The endpoint of the first part of the study is VTE events. The primary outcome will be the DVT-incidence at two weeks, assessed using screening compression duplex ultrasound (CDU) by two ultrasonographers masked to the treatment allocation. Secondary outcome will be the DVT-incidence at 6 weeks. 1\) Deep Vein Thrombosis (DVT) detected by CDU , 2) isolated calf muscle vein thrombosis (ICMVT) detected by CDU, 3) symptomatic DVT or ICMVT detected by CDU, 4) symptomatic pulmonary embolism detected by computer tomography. The endpoint of the second part of the study is tendon healing quantified at 2 weeks by microdialysis followed by quantification of markers for tendon repair. The endpoint of the third part of the study is the functional outcome of the patients at one year post-operatively using four reliable and valid scores, i.e. the Achilles tendon Total Rupture Score (ATRS), Physical Activity scale (PAS), Foot and Ankle Outcome Score (FAOS) and EuroQol Group's questionnaire (EQ-5D) as well as the validated heel-rise test.

Conditions

  • Rupture
  • Venous Thromboembolism
  • Venous Thrombosis
  • Surgical Wound Infection

Interventions

  • Intermittent pneumatic compression (IPC)Device

    6 hours IPC, daily, applied to both calves during two weeks post-operatively. The VenaFlow Elite system (Aircast, Vista, California) uses calf cuffs containing two overlapping air chambers located posteriorly on the leg. As the device cycles, the distal chamber inflates to 52 mm Hg over half a second. During the last 0.2 second of this period, the proximal chamber inflates and reaches 45 mm Hg. After six seconds of inflation the cuff deflates, and the cycle is repeated every minute.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Venous Thromboembolic Events (VTE)Time frame: 2 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Karolinska University Hospital

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.